Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| BioXcel Therapeutics Inc. | Dexmedetomidine (BXCL501) - (TRANQUILITY III) | Agitation associated with Alzheimer’s Disease | Phase 3 | Ongoing | Sublingual | Psychiatric |
| Black Diamond Therapeutics Inc. | Silevertinib (BDTX-1535) | Glioblastoma multiforme (GBM) and NSCLC | Phase 2 | Ongoing | oral | Oncology |
| bluebird bio Inc. | MGTA-145 and plerixafor | Sickle Cell Disease | Phase 2 | Trial Discontinued | Subcutaneous injection | Hematology |
| bluebird bio Inc. | Lenti-D (Elivaldogene Autotemcel / Eli-Cel) - (ALD-102) | Childhood cerebral adrenoleukodystrophy (CCALD) | Phase 2/3 | Ongoing | Intravenous infusion | Genetic Disorder |
| bluebird bio Inc. | Betibeglogene autotemcel (beti-cel) (LentiGlobin) - (HGB-210) | Sickle Cell Disease | Phase 3 | Hold Removed | Intravenous | Hematology |
| bluebird bio Inc. | Betibeglogene autotemcel (beti-cel) (LentiGlobin) - (HGB-210) | Sickle Cell Disease | Phase 3 | Hold Removed | Intravenous | Hematology |
| bluebird bio Inc. | Betibeglogene autotemcel (beti-cel) (LentiGlobin) - (HGB-207 Northstar-2) | non-β0/β0 transfusion-dependent thalassemia (TDT) | Phase 3 | Data Released | Intravenous infusion | Hematology |
| bluebird bio Inc. | Betibeglogene autotemcel (beti-cel) (LentiGlobin) - (HGB-212 Northstar-3) | TDT and the β0/β0genotype | Phase 3 | Trial Completed | Intravenous | Genetic Disorder |
